-

Eureka Therapeutics to Present at Two Upcoming Virtual Conferences

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that it will participate virtually in two upcoming conferences in October:

  • TCR-based Therapies Summit
    Title:     ARTEMIS® Antibody TCR T Cell Therapies for Solid Tumors
    Speaker: Cheng Liu, Ph.D., President and CEO
    Date: Tuesday, October 27, 2020
    Time: 9:00 a.m. EST
  • Cell & Gene Therapy Bioprocessing & Commercialization
    Title:     Optimizing Viral Vector Production
    Speaker: Nicole Nunez, Ph.D., Process Development Scientist
    Date: Thursday, October 22, 2020
    Time: 8:00 a.m. EST

ABOUT EUREKA THERAPEUTICS, INC.

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. ET140203, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.

Contacts

Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com

KKH Advisors
Kimberly Ha
917-291-5744
kimberly.ha@kkhadvisors.com

Industry:

Eureka Therapeutics, Inc.

Release Versions
English

Contacts

Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com

KKH Advisors
Kimberly Ha
917-291-5744
kimberly.ha@kkhadvisors.com

More News From Eureka Therapeutics, Inc.

Eureka’s ARTEMIS® CAR T Cells Show Breakthrough Potential in Solid Tumors in NCI-Led Study Published in Cell Reports Medicine

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies for cancer, today announced the publication of a peer-reviewed study titled “Antibody–Gamma/Delta T Cell Receptors Targeting GPC2 Regress Neuroblastoma with Low Antigen Density” in Cell Reports Medicine. The study, led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, demonstrated that Eureka’s ARTEMIS® CAR T cel...

Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Dr. Reginald Seeto and William S. Solari III to its Board of Directors. Dr. Seeto is a global leader in biopharmaceuticals and diagnostics with expertise in corporate strategy, business development, and operations. He currently serves as President and CEO of Scipher Medicine. Previously, he was President a...

Eureka Therapeutics Adds Stanford Liver Cancer Expert Dr. Samuel So to Scientific Advisory Board

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Samuel So, MBBS, FACS, a globally recognized leader in liver cancer surgery, prevention, and health policy at Stanford University, to its Scientific Advisory Board. Dr. So will provide strategic guidance as Eureka advances its ARTEMIS® CAR-T platform and clinical programs targeting hepatocellular carcinoma...
Back to Newsroom